lenalidomide has been researched along with losartan potassium in 36 studies
| Studies (lenalidomide) | Trials (lenalidomide) | Recent Studies (post-2010) (lenalidomide) | Studies (losartan potassium) | Trials (losartan potassium) | Recent Studies (post-2010) (losartan potassium) |
|---|---|---|---|---|---|
| 3,532 | 725 | 2,850 | 24,390 | 2,493 | 5,408 |
| Protein | Taxonomy | lenalidomide (IC50) | losartan potassium (IC50) |
|---|---|---|---|
| Bile salt export pump | Homo sapiens (human) | 8.53 | |
| Type-1A angiotensin II receptor | Rattus norvegicus (Norway rat) | 0.0082 | |
| Type-1B angiotensin II receptor | Rattus norvegicus (Norway rat) | 0.0049 | |
| Type-2 angiotensin II receptor | Rattus norvegicus (Norway rat) | 0.0082 | |
| 5-hydroxytryptamine receptor 1A | Mus musculus (house mouse) | 0.0082 | |
| Type-1 angiotensin II receptor | Cavia porcellus (domestic guinea pig) | 0.018 |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 14 (38.89) | 29.6817 |
| 2010's | 17 (47.22) | 24.3611 |
| 2020's | 5 (13.89) | 2.80 |
| Authors | Studies |
|---|---|
| Afshari, CA; Chen, Y; Dunn, RT; Hamadeh, HK; Kalanzi, J; Kalyanaraman, N; Morgan, RE; van Staden, CJ | 1 |
| Aul, C; Boultwood, J; Germing, U; Giagounidis, AA; Wainscoat, JS | 1 |
| DeLap, RJ; Knight, R; Zeldis, JB | 1 |
| Nimer, SD | 1 |
| Baker, AF; Bellamy, W; Green, S; List, AF | 1 |
| Goss, TF; Hellström-Lindberg, E; Jädersten, M; Knight, R; List, AF; Schaefer, C; Szende, A; Totten, PJ | 1 |
| Steensma, DP; Tefferi, A | 1 |
| Schiffer, CA | 1 |
| Ohyashiki, K | 1 |
| Cosler, LE; Ferro, SA; Greenberg, PL; Lyman, GH | 1 |
| Hellström-Lindberg, E; Jädersten, M | 1 |
| Stone, RM | 1 |
| Kurtin, SE; List, AF | 1 |
| Ishikawa, T | 1 |
| de Wolf, JT; Huls, G; Mulder, AB; Rosati, S; van de Loosdrecht, AA; Vellenga, E | 1 |
| Lachs, MS; Ritchie, EK | 1 |
| Galili, N; Raza, A | 1 |
| Fenaux, P; Garcia-Manero, G | 1 |
| Altés, A; De Paz, R; del Cañizo, C; López Arrieta, JM | 1 |
| Chen, N; Komrokji, RS; Lancet, JE; List, AF; Lush, R; Paleveda, J; Saba, HI; Swern, AS | 1 |
| Tohyama, K | 1 |
| Meers, S | 1 |
| Birgegård, G | 1 |
| Usuki, K | 1 |
| Banos, A; Benramdane, R; Beyne-Rauzy, O; Bordessoule, D; Bouabdallah, K; Caillot, D; Chevret, S; Cheze, S; Chouffi, B; Cony-Makhoul, P; De Renzis, B; Delaunay, J; Dreyfus, F; Fenaux, P; Fontenay, M; Gardin, C; Gruson, B; Guerci-Bresler, A; Guilhot, F; Gyan, E; Isnard, F; Kosmider, O; Laribi, K; Legros, L; Lejeune, J; Maloum, K; Nimuboma, S; Petit, R; Preudhomme, C; Renneville, A; Rose, C; Salanoubat, C; Sanhes, L; Sardnal, V; Slama, B; Soussain, C; Stamatoullas, A; Taksin, AL; Tertian, G; Toma, A; Wattel, E; Wickenhauser, S | 1 |
| Beyne-Rauzy, O; Chesnais, V; Chevret, S; Delaunay, J; Dreyfus, F; Dumont, F; Fenaux, P; Fontenay, M; Kosmider, O; Lambert, J; Lejeune, J; Passet, M; Preudhomme, C; Raimbault, A; Renneville, A; Rose, C; Solary, E; Stamatoullas, A; Toma, A | 1 |
| Buckstein, R; Rezmovitz, J; Wells, RA | 1 |
| Ades, L; Auberger, P; Basiorka, AA; Cluzeau, T; Fenaux, P; Irvine, B; List, A; Maciejewski, J; Masala, E; McGraw, KL; Santini, V; Wei, S | 1 |
| Giagounidis, A | 1 |
| Abe, M; Arai, N; Ariizumi, H; Baba, Y; Fujiwara, S; Harada, H; Hattori, N; Kabasawa, N; Kawaguchi, Y; Murai, S; Nakamaki, T; Saito, B; Sasaki, Y; Shimada, S; Tsukamoto, H; Uto, Y; Yanagisawa, K | 1 |
| Belickova, M; Cmunt, E; Fuchs, O; Jonasova, A; Michalova, K; Minarik, L; Moudra, A; Neuwirtova, R; Polackova, H; Siskova, M; Stopka, T; Zemanova, Z | 1 |
| Casadevall, N; Gerds, AT; Kelaidi, C; Meunier, M; Park, S; Platzbecker, U | 1 |
| Almeida, A; Beach, CL; Fenaux, P; Giagounidis, A; Santini, V; Skikne, B; Tu, N; Weaver, J | 1 |
| Balleari, E; Campelo, MD; Fenaux, P; Germing, U; Götze, KS; Guerci-Bresler, A; Hamel, JF; Kelaidi, C; Komrokji, R; Kotsianidis, I; Park, S; Santini, V; Sanz, GF; Sekeres, MA; Stamatoullas, A; Steensma, D; Thépot, S; Toma, A | 1 |
| Al Ali, N; Basiorka, AA; Fenaux, P; Fontenay, M; Komrokji, R; Kosmider, O; Lancet, JE; List, AF; McGraw, KL; McLemore, AF; Padron, E; Sallman, DA; Wang, C | 1 |
| Gattermann, N; Germing, U; Kobbe, G; Nachtkamp, K | 1 |
16 review(s) available for lenalidomide and losartan potassium
| Article | Year |
|---|---|
Clinical management of myelodysplastic syndromes with interstitial deletion of chromosome 5q.
Topics: Anemia, Hypochromic; Azacitidine; Bone Marrow; Chromosome Aberrations; Chromosomes, Human, Pair 5; Erythrocyte Transfusion; Erythropoiesis; Erythropoietin; Gene Deletion; Hematinics; Hematopoietic Stem Cell Transplantation; Humans; Karyotyping; Lenalidomide; Myelodysplastic Syndromes; Predictive Value of Tests; Prognosis; Randomized Controlled Trials as Topic; Recombinant Proteins; Thalidomide | 2006 |
Lenalidomide: targeted anemia therapy for myelodysplastic syndromes.
Topics: Anemia; Antineoplastic Agents; Chromosome Deletion; Chromosomes, Human, Pair 5; Drug Delivery Systems; Erythropoiesis; Erythropoietin; Humans; Immunosuppressive Agents; Lenalidomide; Myelodysplastic Syndromes; Randomized Controlled Trials as Topic; Recombinant Proteins; Thalidomide; Treatment Outcome | 2006 |
Risk-based management of myelodysplastic syndrome.
Topics: Anemia, Sideroblastic; Antilymphocyte Serum; Azacitidine; Benzoates; Decitabine; Deferasirox; DNA Modification Methylases; Enzyme Inhibitors; Erythropoietin; Granulocyte Colony-Stimulating Factor; Granulocyte-Macrophage Colony-Stimulating Factor; Histone Deacetylase Inhibitors; Humans; Immunosuppressive Agents; Interleukin-11; Iron Chelating Agents; Lenalidomide; Leukemia, Myelomonocytic, Chronic; Myelodysplastic Syndromes; Prognosis; Risk; Stem Cell Transplantation; Thalidomide; Triazoles | 2007 |
[Development trend in new therapeutic approaches for anemia].
Topics: Anemia; Benzoates; Clinical Trials as Topic; Darbepoetin alfa; Deferasirox; Erythropoietin; Hematinics; Humans; Iron Chelating Agents; Iron Overload; Lenalidomide; Myelodysplastic Syndromes; Neoplasms; Thalidomide; Triazoles | 2008 |
Myelodysplastic syndromes: biology and treatment.
Topics: Antineoplastic Agents; Blood Transfusion; Chromosomes, Human, Pair 5; Disease Progression; Erythropoietin; Female; Humans; Immunosuppressive Agents; Iron Chelating Agents; Lenalidomide; Male; Myelodysplastic Syndromes; Recombinant Proteins; Sequence Deletion; Thalidomide; World Health Organization | 2009 |
How I treat patients with myelodysplastic syndromes.
Topics: Acute Disease; Aged; Azacitidine; Chelation Therapy; Chromosome Deletion; Chromosomes, Human, Pair 5; Clinical Trials as Topic; Decitabine; Disease Progression; DNA Methylation; Erythropoietin; Hematopoietic Cell Growth Factors; Hematopoietic Stem Cell Transplantation; Humans; Iron Chelating Agents; Lenalidomide; Leukemia, Myeloid; Myelodysplastic Syndromes; Severity of Illness Index; Thalidomide; Transplantation, Homologous | 2009 |
[Novel therapeutic agents for myelodysplastic syndrome].
Topics: Antineoplastic Agents; Azacitidine; Clinical Trials as Topic; Decitabine; Drug Discovery; Drug Therapy, Combination; Erythropoietin; Humans; Lenalidomide; Myelodysplastic Syndromes; Randomized Controlled Trials as Topic; Remission Induction; Thalidomide | 2009 |
Pharmacotherapy of myelodysplastic syndromes.
Topics: Azacitidine; Decitabine; DNA Methylation; Drug Approval; Erythropoietin; Humans; Iron Chelating Agents; Lenalidomide; Myelodysplastic Syndromes; Recombinant Proteins; Thalidomide; United States; United States Food and Drug Administration | 2010 |
Hypomethylating agents and other novel strategies in myelodysplastic syndromes.
Topics: Antimetabolites, Antineoplastic; Azacitidine; Decitabine; DNA Methylation; Epoetin Alfa; Erythropoietin; Hematopoietic Stem Cell Transplantation; Humans; Immunosuppressive Agents; Lenalidomide; Myelodysplastic Syndromes; Prognosis; Recombinant Proteins; Thalidomide; Transplantation, Homologous | 2011 |
[Myelodysplastic syndromes: treatment strategy up-to-date].
Topics: Antilymphocyte Serum; Azacitidine; Benzoates; Cyclosporine; Cytarabine; Deferasirox; Disease Progression; Drug Discovery; Drug Therapy, Combination; Erythropoietin; Granulocyte Colony-Stimulating Factor; Hematopoietic Stem Cell Transplantation; Humans; Idarubicin; Immunosuppressive Agents; Iron Chelating Agents; Lenalidomide; Leukemia, Myeloid, Acute; Myelodysplastic Syndromes; Quality of Life; Risk Assessment; Thalidomide; Triazoles | 2014 |
The myelodysplastic syndromes: the era of understanding.
Topics: Angiogenesis Inhibitors; Antimetabolites, Antineoplastic; Azacitidine; Blood Transfusion; Erythropoietin; Gene Expression Regulation, Neoplastic; Hematopoietic Stem Cell Transplantation; Humans; Lenalidomide; Myelodysplastic Syndromes; Neoplasm Proteins; Prognosis; Spliceosomes; Thalidomide; Transplantation, Homologous | 2015 |
Does anything work for anaemia in myelofibrosis?
Topics: Androgens; Anemia; Blood Transfusion; Erythropoietin; Hematinics; Humans; Immunosuppressive Agents; Interferons; Lenalidomide; Nitriles; Oxymetholone; Primary Myelofibrosis; Protein Kinase Inhibitors; Pyrazoles; Pyrimidines; Thalidomide | 2014 |
[Treatment of MDS].
Topics: Allografts; Angiogenesis Inhibitors; Antimetabolites, Antineoplastic; Autografts; Azacitidine; Enzyme Inhibitors; Erythrocyte Transfusion; Erythropoietin; Hematopoietic Stem Cell Transplantation; Histocompatibility; HLA Antigens; Humans; Immunologic Factors; Immunosuppressive Agents; Induction Chemotherapy; Iron Chelating Agents; Lenalidomide; Myelodysplastic Syndromes; Recombinant Proteins; Thalidomide; Transplantation Conditioning | 2014 |
Current treatment algorithm for the management of lower-risk MDS.
Topics: Algorithms; Allografts; Erythrocyte Transfusion; Erythropoietin; Hematinics; Humans; Immunosuppressive Agents; Lenalidomide; Myelodysplastic Syndromes; Stem Cell Transplantation; Thalidomide; Transforming Growth Factor beta | 2017 |
The prognostic value of serum erythropoietin in patients with lower-risk myelodysplastic syndromes: a review of the literature and expert opinion.
Topics: Activin Receptors, Type II; Bone Marrow Cells; Erythropoietin; Female; Ferritins; Hemoglobins; Humans; Immunoglobulin Fc Fragments; Lenalidomide; Male; Myelodysplastic Syndromes; Prognosis; Recombinant Fusion Proteins; Risk Factors | 2020 |
Myelodysplastic Syndromes: New Methods of Diagnosis, Prognostication, and Treatment
Topics: Erythropoietin; Female; Hematopoietic Stem Cell Transplantation; Humans; Lenalidomide; Male; Myelodysplastic Syndromes; Prognosis; Quality of Life | 2023 |
3 trial(s) available for lenalidomide and losartan potassium
| Article | Year |
|---|---|
Combined treatment with lenalidomide and epoetin alfa in lower-risk patients with myelodysplastic syndrome.
Topics: Aged; Antineoplastic Agents; Area Under Curve; Drug Administration Schedule; Drug Therapy, Combination; Erythropoietin; Female; Humans; Lenalidomide; Male; Middle Aged; Myelodysplastic Syndromes; Recombinant Proteins; Risk; Severity of Illness Index; Thalidomide; Thrombocytopenia; Treatment Outcome | 2012 |
Lenalidomide with or without erythropoietin in transfusion-dependent erythropoiesis-stimulating agent-refractory lower-risk MDS without 5q deletion.
Topics: Aged; Anemia; Angiogenesis Inhibitors; Blood Transfusion; Chromosome Deletion; Chromosomes, Human, Pair 5; Drug Therapy, Combination; Erythropoietin; Female; Follow-Up Studies; Humans; Lenalidomide; Male; Middle Aged; Myelodysplastic Syndromes; Neoplasm Staging; Prognosis; Prospective Studies; Risk Factors; Thalidomide | 2016 |
Effect of lenalidomide treatment on clonal architecture of myelodysplastic syndromes without 5q deletion.
Topics: Aged; Anemia, Macrocytic; Antineoplastic Combined Chemotherapy Protocols; Cell Proliferation; Chromosome Deletion; Chromosomes, Human, Pair 5; Clonal Evolution; Clone Cells; DNA Mutational Analysis; Erythropoietin; Female; Humans; Lenalidomide; Male; Myelodysplastic Syndromes; Recombinant Proteins; Thalidomide; Treatment Outcome | 2016 |
17 other study(ies) available for lenalidomide and losartan potassium
| Article | Year |
|---|---|
A multifactorial approach to hepatobiliary transporter assessment enables improved therapeutic compound development.
Topics: Animals; ATP Binding Cassette Transporter, Subfamily B; ATP Binding Cassette Transporter, Subfamily B, Member 11; ATP-Binding Cassette Transporters; Biological Transport; Chemical and Drug Induced Liver Injury; Cluster Analysis; Drug-Related Side Effects and Adverse Reactions; Humans; Liver; Male; Multidrug Resistance-Associated Proteins; Pharmacokinetics; Rats; Rats, Sprague-Dawley; Recombinant Proteins; Risk Assessment; Risk Factors; Toxicity Tests | 2013 |
The 5q- syndrome.
Topics: Age Factors; Antigens, CD; Chromosome Deletion; Chromosomes, Human, Pair 5; Cytogenetics; Erythropoietin; Female; Gene Deletion; Genes, Tumor Suppressor; Humans; Immunosuppressive Agents; Lenalidomide; Male; Myelodysplastic Syndromes; Prognosis; Sex Factors; Thalidomide | 2004 |
Lenalidomide and venous thrombosis in multiple myeloma.
Topics: Anti-Inflammatory Agents; Dexamethasone; Drug Therapy, Combination; Erythropoietin; Humans; Lenalidomide; Multiple Myeloma; Multivariate Analysis; Thalidomide; Venous Thrombosis | 2006 |
Cost effectiveness of lenalidomide in the treatment of transfusion-dependent myelodysplastic syndromes in the United States.
Topics: Antineoplastic Agents; Blood Transfusion; Chromosome Aberrations; Chromosome Deletion; Chromosomes, Human, Pair 5; Cost-Benefit Analysis; Decision Support Techniques; Erythropoietin; Humans; Lenalidomide; Medical Oncology; Models, Econometric; Myelodysplastic Syndromes; Outcome Assessment, Health Care; Quality-Adjusted Life Years; Recombinant Proteins; Risk Factors; Thalidomide; United States | 2006 |
Advances in MDS.
Topics: Antineoplastic Agents; Erythropoietin; Female; Granulocyte Precursor Cells; Hematopoietic Stem Cell Transplantation; Humans; Lenalidomide; Male; Myelodysplastic Syndromes; Thalidomide | 2007 |
The costs of drugs used to treat myelodysplastic syndromes following National Comprehensive Cancer Network Guidelines.
Topics: Anemia; Antineoplastic Agents; Azacitidine; Cost of Illness; Costs and Cost Analysis; Darbepoetin alfa; Decision Support Techniques; Deferoxamine; Drug Costs; Drug Therapy; Epoetin Alfa; Erythropoietin; Hematinics; Humans; Iron Chelating Agents; Lenalidomide; Myelodysplastic Syndromes; Practice Guidelines as Topic; Recombinant Proteins; Siderophores; Thalidomide; United States | 2008 |
Durable long-term responses in patients with myelodysplastic syndromes treated with lenalidomide.
Topics: Administration, Oral; Aged; Aged, 80 and over; Antineoplastic Agents; Chromosomes, Human, Pair 5; Erythrocyte Transfusion; Erythropoietin; Female; Humans; Lenalidomide; Male; Middle Aged; Myelodysplastic Syndromes; Prognosis; Thalidomide; Treatment Outcome | 2009 |
Efficacy of single-agent lenalidomide in patients with JAK2 (V617F) mutated refractory anemia with ring sideroblasts and thrombocytosis.
Topics: Aged, 80 and over; Anabolic Agents; Anemia, Refractory; Anemia, Sideroblastic; Antineoplastic Agents; Erythropoietin; Humans; Hypertension, Pulmonary; Janus Kinase 2; Lenalidomide; Male; Middle Aged; Mutation; Pulmonary Embolism; Pyridoxine; Reverse Transcriptase Polymerase Chain Reaction; Thalidomide; Thrombocytosis; Vitamin B Complex | 2010 |
Management of myelodysplastic syndromes in the geriatric patient.
Topics: Aged; Anemia; Antineoplastic Agents; Azacitidine; Decitabine; Erythrocyte Transfusion; Erythropoietin; Humans; Iron Chelating Agents; Lenalidomide; Myelodysplastic Syndromes; Neutropenia; Thalidomide; Thrombocytopenia | 2009 |
[Myelodysplastic syndrome in the elderly: comprehensive geriatric assessment and therapeutic recommendations].
Topics: Aged; Aged, 80 and over; Antineoplastic Agents; Blood Transfusion; Decision Support Techniques; Deferoxamine; Erythropoietin; Health Status Indicators; Humans; Lenalidomide; Myelodysplastic Syndromes; Prognosis; Siderophores; Thalidomide | 2012 |
Myelodysplastic syndrome.
Topics: Aged; Anemia, Macrocytic; Bone Marrow; Erythropoietin; Fatigue; Humans; Lenalidomide; Myelodysplastic Syndromes; Stem Cell Transplantation; Thalidomide | 2016 |
Pro-inflammatory proteins S100A9 and tumor necrosis factor-α suppress erythropoietin elaboration in myelodysplastic syndromes.
Topics: Calgranulin B; Erythropoiesis; Erythropoietin; Hep G2 Cells; Humans; Lenalidomide; Myelodysplastic Syndromes; Thalidomide; Tumor Necrosis Factor-alpha | 2017 |
Association of red cell distribution width with clinical outcomes in myelodysplastic syndrome.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Azacitidine; Erythroblasts; Erythrocyte Indices; Erythropoiesis; Erythropoietin; Female; Hematopoietic Stem Cell Transplantation; Hemoglobins; Humans; Immunosuppressive Agents; Lenalidomide; Male; Middle Aged; Myelodysplastic Syndromes; Prognosis; Retrospective Studies; Survival Analysis; Young Adult | 2018 |
Lenalidomide treatment in lower risk myelodysplastic syndromes-The experience of a Czech hematology center. (Positive effect of erythropoietin ± prednisone addition to lenalidomide in refractory or relapsed patients).
Topics: Aged; Aged, 80 and over; Chromosomes, Human, Pair 5; Czech Republic; Erythropoietin; Female; Genes, p53; Glucocorticoids; Humans; Immunologic Factors; Lenalidomide; Male; Middle Aged; Myelodysplastic Syndromes; Prednisone; Recurrence; Remission Induction; Risk Factors | 2018 |
Achievement of red blood cell transfusion independence in red blood cell transfusion-dependent patients with lower-risk non-del(5q) myelodysplastic syndromes correlates with serum erythropoietin levels.
Topics: Erythrocyte Transfusion; Erythropoietin; Humans; Lenalidomide; Myelodysplastic Syndromes; Thalidomide | 2020 |
Outcome of lower-risk myelodysplastic syndrome with ring sideroblasts (MDS-RS) after failure of erythropoiesis- stimulating agents.
Topics: Activin Receptors, Type II; Aged; Anemia, Sideroblastic; Azacitidine; Disease Progression; Erythrocyte Transfusion; Erythropoietin; Female; Ferritins; Follow-Up Studies; Hematinics; Humans; Immunoglobulin Fc Fragments; Kaplan-Meier Estimate; Lenalidomide; Male; Proportional Hazards Models; Recombinant Fusion Proteins; Salvage Therapy; Treatment Failure | 2020 |
Dual pyroptotic biomarkers predict erythroid response in lower-risk non-del(5q) myelodysplastic syndromes treated with lenalidomide and recombinant erythropoietin.
Topics: Biomarkers; Chromosome Deletion; Chromosomes, Human, Pair 5; Erythropoietin; Humans; Lenalidomide; Myelodysplastic Syndromes | 2022 |